Acquired Resistance Is Oncogene and Drug Agnostic

Cancer Cell. 2019 Oct 14;36(4):347-349. doi: 10.1016/j.ccell.2019.09.011.

Abstract

Recent approvals of TRK inhibitors have demonstrated the success of a tumor agnostic approach to oncogene-targeted therapy across cancers. Collective data from acquired resistance studies suggest that resistance mechanisms, which include both kinase domain mutations and bypass signaling via RTK-RAS-RAF-MAPK pathways, frequently recur regardless of tumor type, oncogene, and drug.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Drug Resistance, Neoplasm / drug effects*
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Medical Oncology / methods
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Oncogene Proteins, Fusion / antagonists & inhibitors*
  • Oncogene Proteins, Fusion / genetics
  • Oncogenes / genetics
  • Precision Medicine / methods
  • Protein Domains / genetics
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Treatment Outcome

Substances

  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases